237 Ratings
Rs 10,800 Rs 8,000
26 % OFF
ABNORMALITIES OF RET (REARRANGED DURING TRANSFECTION) PROTO-ONCOGENE ON CHROMOSOME 10Q11 HAS BEEN IDENTIFIED AS THE CAUSATIVE GENETIC ABNORMALITY IN NEOPLASIA SUCH AS PAPILLARY THYROID CARCINOMA (10 TO 20%), MULTIPLE ENDOCRINE NEOPLASIA TYPE II (MEN2), MEDULLARY THYOID CARCINOMA & LUNG ADENOCARCINOMAS (1 TO 2%). PATIENTS WITH RET REARRANGEMENTS BENEFIT FROM RET KINASE INHIBITOR THERAPY. THIS TEST IS SPECIALLY RECOMMENDED IN PATIENTS WITH LUNG ADENOCARCINOMA WHO ARE NEGATIVE FOR EGFR MUTATIONS & ALK REARRANGEMENTS.
